

### **Remarks**

Claims 1-32, 34 and 35 are pending in this application. Claim 33 was previously canceled. Claims 1-22 are herein withdrawn in view of Applicants' election. Upon entry of these amendments, claims 1-32, 34 and 35 are pending with claims 23-32, 34 and 35 under active consideration. Applicants respectfully request entry of the amendments and remarks made herein into the file history of the present application.

### **I. ELECTION**

Applicants elect without traverse Group I (claims 23-32, 34 and 35), as drawn to a composition. Applicants further elect without traverse (1) the core compound with multiple R groups of formula I of claim 23 and (2) the species 4-octyl-1-(thiophene-2-sulfonyl)-piperazine-2-carboxylic acid (1-ethyl-2-pyridin-3-yl-1H-benzoimidazol-5-yl) amide, the last compound of claim 31, wherein the R groups of formula I of claim 23 have the following meanings:

- R1 = H
- R2 = 1-ethyl-2-pyridin-3-yl-1H-benzoimidazol-5-yl
- R3 = oct-1-yl
- R4 = thiophene-2-yl

Claims 23-32, 34 and 35 are readable on the elected species. Applicants respectfully submit that the generic claims are allowable and that the remaining species may be properly rejoined and such rejoinder is requested. Applicants expressly reserve the right to prosecute claims directed to the remaining allegedly distinct groups and species in one or more continuing or divisional applications.

### CONCLUSION

The Examiner is hereby respectfully invited to contact the undersigned attorney at the number listed below with any questions, comments or suggestions relating to this application.

Respectfully Submitted,

HOWREY, LLP

Dated: February 27, 2009

By: /David W. Clough/  
David W. Clough, Ph.D.  
Registration No.: 36,107  
Customer No.: 22930  
Telephone No.: (312) 595-1408

HOWREY LLP  
ATTN: Docketing Department  
2941 Fairview Park Drive, Suite 200  
Falls Church, VA 22042-2924  
Telephone No.: (703) 663-3600  
Facsimile No.: (703) 336-6950

**Appendix A**

- |           |  |
|-----------|--|
| Group I   | Claim (s) 23-32, 34 and 35, drawn to a composition.  |
| Group II  | Claim (s) 1-14, drawn to a method of composition use, involving treating infertility.  |
| Group III | Claim (s) 15-22, drawn to a method of composition use, involving treating a disease or disorder associated with phosphodiesterase PDE4, adenosine transporters, or prostanoid receptors. |